Brain Research Bulletin · Nov 16, 2026

Convergent mechanisms between GLP-1 and adenosine in epilepsy: opportunities for therapeutic exploitation?

By Cho H, Boison D

Epilepsy is a serious neurological condition characterized by spontaneous recurrent seizures affecting approximately 83 million people worldwide. Type 2 diabetes (T2D) and obesity are highly prevalent in persons with epilepsy, significantly influencing long-term outcomes, quality of life, and mortality. Traditionally, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat T2D and obesity, and they have recently been highlighted as a therapeutic intervention for neurological disorders, including epilepsy. In epilepsy, adenosine signaling plays a crucial role, as it not only controls seizures but also affects epileptogenesis. As a metabolite and metabolic regulator adenosine is also implicated in the pathophysiology of T2D and obesity. The involvement of adenosine in both conditions raises the possibility of convergent mechanisms implicated in the antiepileptic effects of GLP-1 RAs. This review provides a comprehensive overview of the effects of GLP-1 RAs and adenosine in epilepsy and their convergent mechanisms, which could serve as a basis for synergistic therapeutic applications and insight into their underlying mechanisms. GLP-1 RAs affect several mechanisms shared with adenosine signaling. These include reduction of astrogliosis, neuroinflammation, and mTOR activity, and restoration of the excitation and inhibition balance by suppressing the glutamatergic pathway and upregulating the GABAergic pathway. In peripheral organs, direct convergent mechanisms between adenosine signaling and GLP-1 RAs include interactions between adenosine deaminase and dipeptidylpeptidase-4, lipid metabolism, and pancreatic β-cell homeostasis. These convergent mechanisms highlight the need to further investigate possible bidirectional relationships with the involvement of adenosine in both conditions.

doi.org/10.1016/j.brainresbull.2026.112222PubMed 43039199Interventions

AgingResearch.News